Please assess the completion status of the following clinical trial:

Trial Title: IMM60 and Pembrolizumab in Melanoma and NSCLC

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 6.0

Eligibility Criteria:
Inclusion Criteria:~* Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) score 0 to 1~* Adequate organ function~* At least 1 lesion, not previously irradiated, that can be accurately measured on CT or MRI as defined by RECIST 1.1 criteria~* NSCLC cohorts: Histologically confirmed diagnosis of stage IV NSCLC~* NSCLC cohorts: Patients with adenocarcinoma histology must not have sensitizing epidermal growth factor receptor (EGFR) or ROS proto-oncogene 1 (ROS1) mutations or anaplastic lymphoma kinase (ALK) translocations~* NSCLC cohorts: Participants in NSCLC arms must have a PD-L1 assessment (PD-L1 immuno-histochemistry (IHC) 22C3 pharmDx)~* Melanoma cohorts: Unresectable stage III or IV, histologically confirmed diagnosis of cutaneous or unknown primary melanoma~* Melanoma cohorts: B-type Raf proto-oncogene (BRAF) mutation status available~* Male participants: Participant must agree to use contraception and refrain from sperm donation during the treatment period and for at least 120 days after the last dose of study intervention~* Female participants: Participant is eligible to participate if she is not pregnant, not breastfeeding, and at least one of the following conditions applies:~  1. Not a woman of childbearing potential (WOCBP)~ 2. A WOCBP who agrees to follow contraceptive guidance during the treatment period and for at least 6 months after the last dose of study intervention~Exclusion Criteria:~* Has the following cardiac conditions:~  1. Corrected QT interval (QTc) \> 450 ms~ 2. Uncontrolled hypertension with blood pressure (BP) \> 160/100 despite treatment~ 3. Class II or greater heart failure as defined by the New York Heart Association~ 4. Myocardial infarction within 6 months or angina requiring nitrate therapy more than once a week~* Another active malignancy within the past 2 years (Note: Participants with basal cell carcinoma of the skin, squamous cell carcinoma of the skin, superficial bladder, or carcinoma in situ \[e.g., breast carcinoma, cervical cancer in situ\] that have undergone potentially curative therapy are not excluded. Also, prostate, breast, and neuroendocrine tumors that are stable on hormonal treatment for a period of 1 year or more without the need to adjust dose are not excluded.)~* Has had an allogeneic tissue/solid organ transplant~* Known active central nervous system (CNS) metastases and/or carcinomatous meningitis. Participants with previously treated brain metastases may participate provided they are radiologically stable.~* History of (non-infectious) pneumonitis/interstitial lung disease that required steroids or has current pneumonitis/interstitial lung disease~* Participants with an active autoimmune disease or a documented history of autoimmune disease or syndrome that requires systemic steroids (in dosing exceeding 10 mg daily of prednisone equivalent) or immunosuppressive agents.~* Participants who are known to be serologically positive for Hepatitis B, Hepatitis C, or human immunodeficiency virus.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Phase 1 IMM60 dose escalation safety arm (Type: EXPERIMENTAL): 3 dose levels of IMM60 will be assessed (1, 3, 9 and 36 mg/m\^2 administered IV every 3 weeks for up to 6 cycles)
- Phase 1 IMM60 + pembrolizumab combination safety arm (Type: EXPERIMENTAL): Pembrolizumab 200 mg IV every 3 weeks for up to 35 cycles will be administered in combination with IMM60 IV every 3 weeks for up to 6 cycles. The IMM60 dose will be determined based on the results of the IMM60 dose escalation safety cohort.
- Phase 2 PD-L1 ≥50% NSCLC Cohort 1 (Randomized, IMM60 + pembrolizumab) (Type: EXPERIMENTAL): Pembrolizumab 200 mg IV every 3 weeks for up to 35 cycles will be administered in combination with IMM60 IV every 3 weeks for up to 6 cycles. The IMM60 dose will be determined based on the results of the Phase 1 dose escalation safety cohorts.
- Phase 2 PD-L1 ≥50% NSCLC Cohort 1 (Randomized, pembrolizumab monotherapy) (Type: ACTIVE_COMPARATOR): Pembrolizumab 200 mg IV every 3 weeks for up to 35 cycles.
- Phase 2 PD-L1 <1% NSCLC Cohort 2 (Type: EXPERIMENTAL): Participants will be treated with one cycle of IMM60 with a tumor biopsy before and after, to determine any changes in PD-L1 expression. After this one cycle, the participants will receive the combination of IMM60 IV for up to 6 total cycles + pembrolizumab 200 mg every 3 weeks administered IV. The IMM60 dose will be determined based on the results of the Phase 1 dose escalation cohorts.
- Melanoma Cohort (Type: EXPERIMENTAL): IMM60 IV every 3 weeks for up to 6 cycles. The IMM60 dose will be determined based on the results of the Phase 1 dose escalation cohorts.

Based on this trial design, predict the completion outcome and termination type (if applicable).